With the growing and evolving understanding of chronic myeloid leukemia (CML) biology and its management, therapeutic goals must be continually reassessed to ensure the optimal use of BCR::ABL1 tyrosine kinase inhibitors (TKIs) across both frontline and later-line settings [1, 2]. In chronic-phase CML (CML-CP), frontline imatinib (IM) and second-generation (2 G) TKIs (bosutinib, dasatinib, and nilotinib) provide comparable survival outcomes.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Jiří
Contact Jiří, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack